Pre-Market Earnings Report for April 18, 2023: JNJ, BAC, LMT, GS, and others.
Today, there are several important reports scheduled for release that could impact the market. I see these upcoming releases as an opportunity for growth in the American stock market, and our robots are currently prioritizing long positions. If I had to choose a robot for this week, I would select the Swing Trader Popular Stocks 4K per position Market Neutral Strategy, which can almost always be found in market-neutral positions and tends to generate the highest profit in any market condition.
Johnson & Johnson (JNJ) is set to report its quarterly earnings for the period ending March 31, 2023. According to a consensus of eight analysts who cover the stock, the company is expected to earn $2.51 per share. This represents a 5.99% decline compared to the same quarter in the previous year. However, JNJ has surpassed analysts' expectations in every quarter of the past year, with its biggest beat occurring in the fourth quarter, where it outperformed consensus estimates by 5.86%.
The Bank of America Corporation (BAC) is expected to report its earnings for the quarter ending March 31, 2023. The consensus earnings per share forecast from 11 analysts who follow the stock is $0.79, which is a 1.25% decrease compared to the same quarter last year. In the 2nd calendar quarter of 2022, BAC missed the consensus earnings per share by -5.19%.
Lockheed Martin Corporation (LMT) is expected to report its quarterly earnings for the period ending March 31, 2023. According to the consensus forecast of 6 analysts following the stock, the aerospace and defense company is expected to report earnings per share of $6.08, which represents a 5.59% decrease compared to the same quarter last year. However, it's worth noting that LMT has exceeded expectations in every quarter of the past year, with the highest beat occurring in the 4th calendar quarter by 5.13%.
Goldman Sachs Group, Inc. (GS) is expected to report earnings for the quarter ending March 31, 2023. The consensus earnings per share forecast from the 8 analysts that follow the stock is $8.14, which represents a significant 24.35% decrease compared to the same quarter last year. In the 4th calendar quarter of 2022, GS missed the consensus earnings per share by -36.76%.
ProLogis, Inc. (PLD) is expected to report a Q1 2023 earnings per share of $1.21, representing an 11.01% increase compared to the same quarter last year. In the 2nd calendar quarter of 2022, PLD missed the consensus earnings per share by -0.89%.
The Bank of New York Mellon Corporation (BK) is expected to report a Q1 2023 earnings per share of $1.09, representing a 26.74% increase compared to the same quarter last year. In the past year, BK has met analyst expectations once and beat expectations the other three quarters.
Ericsson (ERIC) is expected to report a Q1 2023 earnings per share of $0.04, representing a 60.00% decrease compared to the same quarter last year.
Commerce Bancshares, Inc. (CBSH) is expected to report a Q1 2023 earnings per share of $0.91, representing a 1.09% decrease compared to the same quarter last year. In the 3rd calendar quarter of 2022, CBSH missed the consensus earnings per share by -2.02%.
Mercantile Bank Corporation (MBWM) is expected to report a Q1 2023 earnings per share of $1.15, representing a 57.53% increase compared to the same quarter last year. In the past year, MBWM has met analyst expectations once and beat expectations the other three quarters.
JNJ in +0.64% Uptrend, growing for three consecutive days on October 13, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where JNJ advanced for three days, in of 347 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 26, 2025. You may want to consider a long position or call options on JNJ as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on September 29, 2025. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JNJ broke above its upper Bollinger Band on September 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on September 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.869) is normal, around the industry mean (9.662). P/E Ratio (18.471) is within average values for comparable stocks, (24.491). Projected Growth (PEG Ratio) (1.101) is also within normal values, averaging (2.055). Dividend Yield (0.027) settles around the average of (0.028) among similar stocks. P/S Ratio (5.033) is also within normal values, averaging (3.576).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement